Use of Propofol as a Sedative Agent Versus Spinal Analgesia With Bupivacaine in External Cephalic Version

Last updated: June 3, 2024
Sponsor: Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pregnancy Complications

Treatment

Sedation with propofol

Spinal analgesia with bupivacaine

Clinical Study ID

NCT06449430
IMIB-ECV-2024-01
  • Ages > 18
  • Female

Study Summary

External Cephalic Version (ECV) is a maneuver to modify fetal position in pregnant women with a non-cephalic presentation. Its objective is to achieve a cephalic presentation that allows for vaginal delivery with less risk than a vaginal breech delivery or a cesarean section. ECV is an effective technique to reduce the rate of cesarean sections and is recommended by the Spanish Society of Obstetrics and Gynecology (SEGO) and the World Health Organization (WHO) Cesarean Section Working Group. The WHO aims to reduce interventionism in childbirth globally and implement non-clinical measures to reduce the rate of unnecessary cesarean sections.

Despite Propofol is a sedative agent commonly used by anesthesiologist in countless ambulatory procedures in obstetric anaesthesia, it has been little studied in ECV, and its effect has not been compared with other commonly used agents such as remifentanil or spinal analgesia. The Obstetric Anesthesiology Section of the Spanish Society of Anesthesiology and Resuscitation recommends the use of locoregional analgesia in ECV.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Voluntary participation.

  • Older than 18 years.

  • Non-cephalic presentation.

  • Desire to attempt a vaginal birth.

  • Normal blood count and coagulation prior to the intervention

Exclusion

Exclusion Criteria:

  • Age under 18 years old.

  • Multiple gestation.

  • Cephalic presentation.

  • Risk of fetal compromise.

  • Unexplained active bleeding.

  • Absolute contraindication for vaginal delivery (Placenta Previa)

  • 2 or more previous cesarean sections.

  • Previous myomectomy with entry into the uterine cavity

  • Maternal fever.

  • Thrombocytopenia (<85,000 platelets).

  • Maternal spinal anomaly.

  • Intolerance or allergy to Propofol or any of its components.

  • Intolerance or allergy to bupivacaine or any of its components.

  • Contraindication for intrathecal sedation or analgesia

Study Design

Total Participants: 270
Treatment Group(s): 2
Primary Treatment: Sedation with propofol
Phase:
Study Start date:
May 28, 2024
Estimated Completion Date:
September 30, 2025

Study Description

This project involves a randomized clinical trial to compare the effect of sedation with propofol versus spinal analgesia in ECV. Therefore, the objectives of this study are:

  • To compare the effect of sedation with Propofol on the success rate of ECV compared to spinal analgesia.

  • To compare the effect of sedation with Propofol on the rate of complications of ECV compared to spinal analgesia.

  • To compare the effect of sedation with Propofol on the length of hospital stay of ECV compared to spinal analgesia.

Locoregional analgesia requires a longer hospital stay than sedation with Propofol and may mask an early diagnosis of complications after ECV, such as placental abruption, which is identified in the initial stages by intense abdominal pain.

Connect with a study center

  • Hospital Clínico Universitario Virgen de la Arrixaca

    Murcia, 30120
    Spain

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.